This study is for adults with advanced breast cancer that has spread and has a protein called HER2 on the tumor. It aims to test a medicine called disitamab vedotin, given through a vein every two weeks. HER2 is a protein that can make cancer grow faster. Participants will get this medicine until it's decided to stop, either by them or their doctor. The study will track how people respond to the treatment in terms of safety and effectiveness.

Key Points:

• Participants get an intravenous (IV) infusion every two weeks.
• Follow-up visits continue every 6 weeks after stopping the medicine.
• The study includes follow-up phone calls every 12 weeks.

This study is for people who have already tried other treatments for advanced breast cancer. It helps researchers learn if this new medicine can help treat this type of cancer. Participants will need to visit the study clinic regularly and be open to follow-up checks even after stopping the treatment.